KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

KRAS mutation occurs in nearly 30% of human cancers, yet the most prevalent and oncogenic KRAS(G12D) variant still lacks inhibitors. Herein, we designed a series of potent inhibitors that can form a salt bridge with KRAS’s Asp12 residue. Our ITC results show that these inhibitors have similar bindin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Zhongwei, Xiao, Hongying, Shen, Panpan, Yang, Yu, Xue, Jing, Yang, Yunyun, Shang, Yanguo, Zhang, Lilan, Li, Xin, Zhang, Yuying, Du, Yanan, Chen, Chun-Chi, Guo, Rey-Ting, Zhang, Yonghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786924/
https://www.ncbi.nlm.nih.gov/pubmed/35075146
http://dx.doi.org/10.1038/s41421-021-00368-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786924/
https://www.ncbi.nlm.nih.gov/pubmed/35075146
http://dx.doi.org/10.1038/s41421-021-00368-w

Ejemplares similares